New triple therapy aims to shrink tough lung tumors
NCT ID NCT07318883
First seen Jan 08, 2026 · Last updated May 12, 2026 · Updated 19 times
Summary
This study tests whether adding an experimental drug (HLX07) to standard immunotherapy and chemotherapy can better control advanced squamous non-small cell lung cancer. About 720 adults with stage 3 or 4 disease will receive either the new combination or standard treatment. The goal is to see if the new mix shrinks tumors and extends life without major side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.